Latest News and Press Releases

Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January...

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...

BOWDEN, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Protein Industries Canada and a consortium of partners, including More Than Protein Ingredients Ltd., Quantum Mechanical Technology Inc. and...

BOWDEN, Alberta, March 15, 2022 (GLOBE NEWSWIRE) -- More Than Protein Ingredients Ltd., Quantum Mechanical Technology Inc. and Hamman Ag Research Inc., with the support of Protein Industries Canada,...

Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...

CALGARY, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Today, Protein Industries Canada announced a project to establish lupin as a staple crop in the Canadian agrifood sector. Lupin Platform Inc., Hensall...

Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Prils Market accounted for US$ 2388.6 million in 2020 and is estimated to be US$ 3496.8 million by 2030 and is anticipated to register a...

US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...